跳至主要内容
临床试验/NCT00005957
NCT00005957已完成不适用

A Phase III Study of Regional Radiation Therapy in Early Breast Cancer

NCIC Clinical Trials Group52 个研究点 分布在 1 个国家目标入组 1,832 人开始时间: 2000年3月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,832
试验地点
52
主要终点
Overall Survival

研究概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation to the tumor site and surrounding area may kill more tumor cells. It is not yet known if radiation therapy to the breast alone following surgery is more effective than radiation therapy to the breast plus surrounding tissue in treating invasive breast cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy to the breast alone to see how well it works compared to radiation therapy to the breast plus surrounding tissue in treating women who have undergone surgery for early-stage invasive breast cancer.

详细描述

OBJECTIVES:

  • Compare the overall survival, disease-free survival, isolated local regional disease-free survival, and distant disease-free survival in women with previously resected, early stage, invasive breast cancer treated with breast radiotherapy with or without regional radiotherapy.
  • Compare the toxic effects of these regimens in these patients.
  • Compare the quality of life of patients (in certain participating centers) treated with these regimens.
  • Compare the cosmetic outcomes in patients (in certain participating centers) treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number of positive nodes (0 vs 1-3 vs more than 3), number of axillary nodes removed (<10, > or equal to 10); type of chemotherapy (anthracycline containing vs other vs none), hormonal therapy (yes vs no), number of axillary lymph nodes excised*, and participating center. Patients are randomized to one of two treatment arms.

NOTE: * Patients with a negative sentinel node dissection with or without an axillary dissection will be stratified according to the total number of nodes removed

  • Arm I: Patients undergo standard breast radiotherapy alone 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients undergo breast and regional radiotherapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 120 Years(Child, Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Overall Survival

时间窗: 10 years

Duration of study

次要结局

  • Disease-free Survival(10 years)

研究者

申办方类型
Network
责任方
Sponsor

研究点 (52)

Loading locations...

相似试验

Radiation Therapy in Treating Women Who Have... | 临床试验